JP2022521446A - 発作制御を改善するための製剤 - Google Patents
発作制御を改善するための製剤 Download PDFInfo
- Publication number
- JP2022521446A JP2022521446A JP2021572257A JP2021572257A JP2022521446A JP 2022521446 A JP2022521446 A JP 2022521446A JP 2021572257 A JP2021572257 A JP 2021572257A JP 2021572257 A JP2021572257 A JP 2021572257A JP 2022521446 A JP2022521446 A JP 2022521446A
- Authority
- JP
- Japan
- Prior art keywords
- patient
- fenfluramine
- day
- days
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962810228P | 2019-02-25 | 2019-02-25 | |
| US62/810,228 | 2019-02-25 | ||
| PCT/US2020/018359 WO2020176276A1 (en) | 2019-02-25 | 2020-02-14 | A formulation for improving seizure control |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022521446A true JP2022521446A (ja) | 2022-04-07 |
| JP2022521446A5 JP2022521446A5 (cg-RX-API-DMAC10.html) | 2022-12-07 |
Family
ID=72239800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021572257A Pending JP2022521446A (ja) | 2019-02-25 | 2020-02-14 | 発作制御を改善するための製剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20220133652A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3930841A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2022521446A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2020176276A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220044380A (ko) | 2013-04-12 | 2022-04-07 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 외상후 스트레스 장애의 치료 방법 |
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| DK3800177T3 (da) | 2015-12-22 | 2025-03-31 | Zogenix International Ltd | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme |
| US10689324B2 (en) | 2015-12-22 | 2020-06-23 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| RU2021106383A (ru) | 2016-08-24 | 2021-04-05 | Зодженикс Интернэшнл Лимитед | Состав для ингибирования образования агонистов 5-ht2b и способы его применения |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| CA3097335A1 (en) | 2018-05-11 | 2019-11-14 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| WO2020105005A1 (en) | 2018-11-19 | 2020-05-28 | Zogenix International Limited | Methods of treating rett syndrome using fenfluramine |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| GB2597323A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| US20240197704A1 (en) * | 2021-04-09 | 2024-06-20 | Johns Hopkins University | Treatment methods and compositions comprising perampanel |
| EP4351727A4 (en) * | 2021-05-28 | 2025-01-01 | Icahn School of Medicine at Mount Sinai | METHOD OF TREATMENT OF DRUG-RESISTANT EPILEPSY |
| US12667723B2 (en) | 2022-04-08 | 2026-06-30 | Patrick M. Nemechek | Systems and methods for treating autism spectrum disorder, developmental disorders and other medical conditions |
| CN117530933B (zh) * | 2024-01-10 | 2024-05-10 | 江苏长泰药业股份有限公司 | 一种吡仑帕奈长效缓释微球、制备方法及缓释注射剂 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110230473A1 (en) * | 2008-10-10 | 2011-09-22 | Gordon Richard K | Methods and Compositions for Treating Status Epilepticus and Seizures Causing Status Epilepticus |
| US20120157392A1 (en) * | 2004-05-07 | 2012-06-21 | Btg International Limited | Epilepsy treatment employing ketogenic compounds which arrest apoptosis |
| JP2016518387A (ja) * | 2013-05-03 | 2016-06-23 | カトリック ユニバーシテイト ルーベン | ドラベ症候群の処置における使用のためのフェンフルラミン |
| JP2018504420A (ja) * | 2015-02-06 | 2018-02-15 | マリナス ファーマシューティカルズ インコーポレイテッド | 静注用ガナキソロン製剤ならびにてんかん重積状態および他の発作性障害の治療におけるその使用 |
| JP2018525418A (ja) * | 2015-08-24 | 2018-09-06 | ゾゲニクス インターナショナル リミテッド | フェンフルラミンを用いたレノックス・ガストー症候群の処置方法 |
-
2020
- 2020-02-14 WO PCT/US2020/018359 patent/WO2020176276A1/en not_active Ceased
- 2020-02-14 JP JP2021572257A patent/JP2022521446A/ja active Pending
- 2020-02-14 EP EP20762650.8A patent/EP3930841A4/en not_active Withdrawn
- 2020-02-14 US US17/430,033 patent/US20220133652A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120157392A1 (en) * | 2004-05-07 | 2012-06-21 | Btg International Limited | Epilepsy treatment employing ketogenic compounds which arrest apoptosis |
| US20110230473A1 (en) * | 2008-10-10 | 2011-09-22 | Gordon Richard K | Methods and Compositions for Treating Status Epilepticus and Seizures Causing Status Epilepticus |
| JP2016518387A (ja) * | 2013-05-03 | 2016-06-23 | カトリック ユニバーシテイト ルーベン | ドラベ症候群の処置における使用のためのフェンフルラミン |
| JP2018504420A (ja) * | 2015-02-06 | 2018-02-15 | マリナス ファーマシューティカルズ インコーポレイテッド | 静注用ガナキソロン製剤ならびにてんかん重積状態および他の発作性障害の治療におけるその使用 |
| JP2018525418A (ja) * | 2015-08-24 | 2018-09-06 | ゾゲニクス インターナショナル リミテッド | フェンフルラミンを用いたレノックス・ガストー症候群の処置方法 |
Non-Patent Citations (2)
| Title |
|---|
| BRAIN, vol. 134, JPN6023045178, 2011, pages 2802 - 2818, ISSN: 0005329878 * |
| THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, vol. 8, no. 6, JPN6023045177, 2015, pages 328 - 338, ISSN: 0005188794 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3930841A4 (en) | 2022-11-30 |
| WO2020176276A1 (en) | 2020-09-03 |
| EP3930841A1 (en) | 2022-01-05 |
| US20220133652A1 (en) | 2022-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220133652A1 (en) | A formulation for improving seizure control | |
| US20220249515A1 (en) | Ganaxolone for use in treating genetic epileptic disorders | |
| US20200276136A1 (en) | Method of treating selected patient population experiencing dravet syndrome | |
| Urits et al. | A review of patisiran (ONPATTRO®) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis | |
| US12036190B2 (en) | Methods and compositions for the treatment of cytoplasmic glycogen storage disorders | |
| US20240238222A1 (en) | Methods of treating lennox-gastaut syndrome using fenfluramine | |
| US20190247333A1 (en) | Method of reduction in convulsive seizure frequency | |
| US20250281477A1 (en) | Treatment of cns conditions | |
| JP2023071832A (ja) | フェンフルラミンを用いるドゥーゼ症候群の治療方法 | |
| WO2019067413A1 (en) | USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS | |
| EP3883555A1 (en) | Methods of treating rett syndrome using fenfluramine | |
| JP7830358B2 (ja) | カンナビジオールによる脆弱x症候群の処置 | |
| JP2020535227A (ja) | ケトン食療法に適合したフェンフルラミン製剤 | |
| EP3131545B1 (en) | Use of enoximone in the treatment of atopic immune-related disorders, in pharmaceutical compositions as well as in pharmaceutical preparations | |
| EA052165B1 (ru) | Ганаксолон для использования в лечении наследственных эпилептических заболеваний | |
| HK1233956B (en) | Use of enoximone in the treatment of atopic immune-related disorders, in pharmaceutical compositions as well as in pharmaceutical preparations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220204 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221129 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221129 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20230530 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231102 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240523 |